Composition for improving hyperglycemia of pets and preparation method thereof

Abstract

A composition for improving hyperglycemia of pets and a preparation method thereof belong to the field of health food for pets, are used for improving symptoms of hyperglycemia of pets, and are characterized by comprising 20-50 parts of sea cucumber oligopeptide, 10-30 parts of sea cucumber polysaccharide, 20-40 parts of a ginseng extract, 20-30 parts of an acanthopanax sessiliflorus extract, 10-20 parts of a white kidney bean extract and 10-20 parts of a poria cocos extract. According to the present invention, starting from the mechanism that glucose promotes insulin secretion, the pancreas islet beta cells are protected from excessive stimulation so as to have a rest, and the functional components directly protect and repair the pancreas, such that the normal function of the pancreas is recovered, and the continuous development of hyperglycemia to diabetes mellitus is blocked.

Description

Technical Field

[0001] The invention belongs to the field of pet health food, and particularly relates to a composition for improving pet hyperglycemia and a preparation method thereof. Background Art

[0002] With the improvement of living standards, more and more people and families are starting to keep pets, and the status of pets in people's lives is becoming more and more important. At present, the number of pet cats and dogs in my country has exceeded 120 million, and is still growing. The growth in the number of pets and the number of people who keep pets has also driven the vigorous development of the pet industry, with an endless stream of various pet products, constantly updated scientific feeding methods, and increasingly improved pet medical care. At the same time, various health problems and diseases of pets are becoming increasingly prominent.

[0003] Hyperglycemia is a metabolic disease characterized by high blood sugar due to defective insulin secretion or its biological function. Long-term high blood sugar will gradually develop into diabetes and cause chronic damage and dysfunction of various tissues and organs, especially the kidneys, eyes, heart, blood vessels and nerves. The incidence of diabetes in dogs and cats is about 0.2% to 1%, and the upward trend is obvious. Hyperglycemia and diabetes have become prominent problems threatening the health of pets.

[0004] However, currently pet owners basically only start to discover, pay attention to and treat their pets after they develop diabetes, and the methods are relatively simple, mainly through controlling the pet's diet or injecting insulin to lower blood sugar for treatment. Dietary control mainly controls postprandial blood sugar by letting pets eat small meals and limiting food intake, which may delay the onset of some complications. There are already some low-starch, low-sugar, high-protein diabetes prescription food products on the market. Although insulin injection can quickly lower blood sugar, it is expensive and may have adverse reactions, such as allergies, redness, swelling, itching, edema at the injection site, etc., and it may also pierce small nerves during injection, causing pain and struggle in animals. Insulin injection requires high dosage accuracy. Excessive doses are prone to hypoglycemia. In mild cases, dogs may experience increased appetite, weakness, and dizziness, and cats may experience irritability, tremors, spasms, dilated pupils, weakness, depression, etc. In severe cases, loss of consciousness, convulsions, or even coma may occur; if insufficient insulin is injected, blood sugar cannot be fully reduced, and the significance of the injection is weakened and the effect cannot be achieved.

[0005] Whether it is controlling the pet's diet or injecting insulin, it is only a temporary solution and cannot fundamentally solve the problem. A good doctor treats the disease before it occurs. Diabetes begins with persistent high blood sugar, so the real care for the health of pets must be immediately controlled and treated from the time of persistent high blood sugar. The current market lacks relevant research, especially in the pet industry, which is still in its infancy. Therefore, when pets have high blood sugar but have not yet developed diabetes, developing a health product that effectively lowers blood sugar is of great significance for improving pet health, improving pet quality of life, and extending the time spent with pet owners, and even helping pet owners with emotional value. Summary of the invention

[0006] In view of the above pet health problems and market demands, the present invention provides a composition for improving pet hyperglycemia and a preparation method thereof.

[0007] The technical solutions adopted by the present invention to achieve the above-mentioned purpose are as follows:

[0008] A composition for improving pet hyperglycemia comprises: 20-50 parts of sea cucumber oligopeptides, 10-30 parts of sea cucumber polysaccharides, 20-40 parts of ginseng extract, 20-30 parts of Acanthopanax brevis extract, 10-20 parts of white kidney bean extract, and 10-20 parts of Poria cocos extract.

[0009] Furthermore, sea cucumber oligopeptides and sea cucumber polysaccharides are prepared based on the following method: dry sea cucumber is crushed, 5-7 times the mass of water is added and boiled for 30 minutes, then the mixture is homogenized by a colloid mill, and then 5-10 times the mass of water is added and stirred evenly. The feed liquid is ultrasonicated at 300-400W for 40-60 minutes, then the feed liquid temperature is adjusted to 50-55°C, pH7.0-8.0, and a composite enzyme (papain: medium temperature α-amylase = 1: (1-3)) with a volume of 0.2-0.5% of the feed liquid is added and stirred for enzymolysis for 2-3 hours to obtain a first enzymolysis solution; then the feed liquid temperature is adjusted to 55-60°C, pH8.0-9.0, and a composite protease (trypsin: alkaline protease: neutral protease = (3-5): (2-4): (1-2)) with a volume of 0.2-0.5% of the feed liquid is added, and the enzymolysis is stirred for 3-5 hours to obtain a second enzymolysis solution. The second enzymatic hydrolysate is centrifuged, the clear liquid is passed through a membrane device with a molecular weight cutoff of 3000Da, the permeate is concentrated and then spray-dried to obtain sea cucumber oligopeptides, and the retentate is concentrated and then freeze-dried to obtain sea cucumber polysaccharides.

[0010] Furthermore, the raw material of the sea cucumber oligopeptide and sea cucumber polysaccharide is sea cucumber, preferably sea cucumber Liao and sea cucumber Mi.

[0011] Furthermore, the sea cucumber polysaccharide is a low molecular weight sea cucumber polysaccharide, with a weight average molecular weight of <25kD, a polysaccharide content of >50%, a sulfate group content of ≥20%, and no free sulfate groups were detected.

[0012] Furthermore, sea cucumber oligopeptides are small molecule active peptides, with a peptide content of >80%, of which more than 95% of the peptides have a molecular weight of less than 1000Da.

[0013] Furthermore, the raw material of the ginseng extract is Changbai Mountain ginseng, which is extracted by an enzymatic hydrolysis process, wherein the total ginsenoside content is ≥3%, the peptide content is ≥15%, and more than 80% of the peptides have a molecular weight of less than 1000Da.

[0014] Furthermore, the Acanthopanax breviscapus extract is obtained by enzymatic extraction, wherein the total saponins are ≥ 2.0% and the total flavonoids are ≥ 0.3%.

[0015] Furthermore, the white kidney bean extract is obtained by enzymatic extraction, wherein the α-amylase inhibitor activity is ≥2000u / g, and the lectin activity is ≤0.4mg / mL.

[0016] Furthermore, the Poria cocos extract is obtained by enzymatic extraction, wherein the Poria cocos polysaccharide is ≥ 20%.

[0017] Furthermore, the composition for improving pet hyperglycemia can be in the form of powder, granules, tablets, capsules, pills, and oral liquid.

[0018] Glucose is oxidized by the specific K ATP The K channel promotes the secretion of insulin by pancreatic β cells. When the intracellular glucose concentration increases, the ATP / ADP ratio increases, and K ATP Channel closure causes Ca 2+ Channel opening, intracellular Ca 2+ Rising concentration triggers insulin release. Symptoms of high blood sugar have always accompanied the occurrence and development of diabetes. This persistent high blood sugar "toxicity" will over-stimulate the pancreatic beta cells to secrete insulin, gradually leading to insulin resistance and impaired pancreatic beta cell function, and developing into diabetes. In the period when high blood sugar occurs but has not yet developed into diabetes, measures should be taken to reduce this persistent high blood sugar "toxicity" so that the pancreatic beta cells are not over-stimulated and insulin is not over-secreted, so that the pancreatic beta cells can rest and repair, gradually restore normal function, and block the progression of diabetes and organ and tissue complications.

[0019] Sea cucumber polysaccharides promote the production of liver glycogen and muscle glycogen by improving glucose transport and metabolism, lowering glucose levels and alleviating the stimulation of hyperglycemia on pancreatic β cells.

[0020] Sea cucumber oligopeptides can lower fasting blood sugar, while increasing the organ indexes of the thymus, spleen, liver, and kidneys. They have a good effect on protecting and repairing internal organs, and avoid complications of organ damage caused by the "toxicity" of persistent high blood sugar.

[0021] Ginseng extract contains small molecule peptides and ginsenosides. Ginseng small molecule peptides can regulate sugar and lipid metabolism, inhibit the rise of blood sugar after meals, and improve insulin sensitivity. Ginsenosides have an important effect on K ATP The channels have an opening effect and reduce insulin secretion, which have an indirect protective effect on pancreatic β cells.

[0022] Acanthopanax short-stalk extract contains saponins, which are important for K ATP The channel has an opening effect, reducing insulin secretion and allowing pancreatic beta cells to rest.

[0023] White kidney bean extract contains α-amylase inhibitor activity, which hinders the digestion and decomposition of carbohydrates by blocking the combination of starch and α-amylase, slowing down the rate of glucose absorption, which is beneficial for postprandial blood sugar control, maintaining blood sugar stability, and reducing insulin requirements.

[0024] In traditional Chinese medicine, the pancreas belongs to the category of spleen. Poria cocos itself has the effect of strengthening the spleen. The prepared Poria cocos extract is rich in Poria cocos polysaccharides, which has the effects of resisting lipid peroxidation, reducing the production of free radicals, and reducing the damage of pancreatic beta cells, and has a better effect on the health care and repair of the pancreas.

[0025] Beneficial effects of the present invention:

[0026] 1. The present invention provides a solution before the pet's high blood sugar develops into diabetes. The raw materials of the composition of the present invention are easy to obtain, the preparation process is simple, and it is easy to realize industrial production. In addition, the product mechanism is clear, the effect is significant, and it is safe to eat, and the market prospect is broad.

[0027] 2. Regulate blood sugar through multiple pathways to avoid the problem of unstable regulation and poor effect of a single pathway. Starting from the mechanism of glucose promoting insulin secretion, on the one hand, by reducing the cellular glucose level, the ATP / ADP ratio is reduced, and on the other hand, K ATP Channels, promoting their opening, the two aspects work together to reduce the "toxicity" of sustained high blood sugar, while improving insulin sensitivity, reducing insulin resistance, and indirectly alleviating the pressure on pancreatic beta cells. The three aspects work synergistically to protect pancreatic beta cells from over-stimulation and prevent excessive insulin secretion.

[0028] 3. Protect pancreatic beta cells from over-stimulation. While allowing them to rest, the active ingredients directly protect and repair the pancreas, restoring its normal function and blocking the development of persistent high blood sugar into diabetes. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 Changes in fasting blood sugar in the blue cat group before and after 4 weeks of feeding.

[0030] Figure 2 Changes in fasting blood glucose in the Burmese cat group before and after 4 weeks of feeding. DETAILED DESCRIPTION

[0031] Example 1: A composition for improving hyperglycemia in pets, comprising: 20 parts of sea cucumber oligopeptides, 20 parts of sea cucumber polysaccharides, 20 parts of ginseng extract, 20 parts of Acanthopanax brevis extract, 10 parts of white kidney bean extract, and 10 parts of Poria cocos extract.

[0032] Preparation method, comprising

[0033] (1) Preparation of sea cucumber oligopeptides and sea cucumber polysaccharides: The dried sea cucumber was crushed, 5 times the mass of water was added and boiled for 30 minutes, then homogenized by a colloid mill, and then 10 times the mass of water was added and stirred evenly. The feed liquid was ultrasonicated at 400W for 50 minutes, then the feed liquid temperature was adjusted to 50°C, pH7.0, and 0.3% of the feed liquid volume of the composite enzyme (papain: medium temperature α-amylase = 1:2) was added and stirred for enzymolysis for 2 hours; then the feed liquid temperature was adjusted to 55°C, pH8.5, and 0.3% of the feed liquid volume of the composite protease (trypsin: alkaline protease: neutral protease = 3:2:1) was added and stirred for enzymolysis for 4 hours. The enzymolysis solution was centrifuged, and the clear solution was passed through a membrane device with a molecular weight cutoff of 3000. The permeate was concentrated and spray-dried to obtain sea cucumber oligopeptides, and the retentate was concentrated and freeze-dried to obtain sea cucumber polysaccharides.

[0034] (2) Accurately weigh 20 parts of sea cucumber oligopeptides, 20 parts of sea cucumber polysaccharides, 20 parts of ginseng extract, 20 parts of Acanthopanax brevis extract, 10 parts of white kidney bean extract, and 10 parts of Poria cocos extract, place them in a blender and mix for 15 minutes, and then use an automatic packaging machine to package them to obtain a powder product.

[0035] The weight average molecular weight of sea cucumber polysaccharide is 21.6kD, the polysaccharide content is 53.4%, the sulfate group content is 21.8%, and free sulfate groups are not detected.

[0036] The peptide content of sea cucumber oligopeptides is 83.4%, of which peptides with a molecular weight of less than 1000Da account for 95.3%.

[0037] The ginseng extract prepared by enzymatic hydrolysis of Changbai Mountain ginseng contains 3.51% total ginsenosides, 18.4% peptides, and 86.4% peptides with a molecular weight of less than 1000Da.

[0038] The total saponin content of the Acanthopanax breviscapus extract prepared by enzymatic hydrolysis was 2.3%, and the total flavonoid content was 0.5%.

[0039] The α-amylase inhibitor activity of the white kidney bean extract prepared by enzymatic hydrolysis was 2200u / g, and the lectin activity was 0.31mg / mL.

[0040] The content of pachymaran in the pachymar extract prepared by enzymatic hydrolysis is 26.4%.

[0041] Example 2: A composition for improving hyperglycemia in pets, comprising: 25 parts of sea cucumber oligopeptides, 30 parts of sea cucumber polysaccharides, 25 parts of ginseng extract, 25 parts of Acanthopanax brevis extract, 15 parts of white kidney bean extract, and 20 parts of Poria cocos extract.

[0042] The preparation method comprises:

[0043] (1) Preparation of sea cucumber oligopeptides and sea cucumber polysaccharides: Dried sea cucumbers were crushed, 7 times the weight of water was added and boiled for 30 minutes, then homogenized by a colloid mill, and then 8 times the weight of water was added and stirred evenly. The feed liquid was ultrasonicated at 400W for 60 minutes, then the feed liquid temperature was adjusted to 55℃, pH7.5, and 0.5% of the feed liquid volume of the composite enzyme (papain: medium temperature α-amylase = 1:3) was added and stirred for enzymolysis for 3 hours; then the feed liquid temperature was adjusted to 55℃, pH9.0, and 0.5% of the feed liquid volume of the composite protease (trypsin: alkaline protease: neutral protease = 3:4:1) was added, and stirred for enzymolysis for 5 hours. The enzymolysis solution was centrifuged, and the clear solution was passed through a membrane device with a molecular weight cutoff of 3000. The permeate was concentrated and spray-dried to obtain sea cucumber oligopeptides, and the retentate was concentrated and freeze-dried to obtain sea cucumber polysaccharides.

[0044] (2) Accurately weigh 25 parts of sea cucumber oligopeptides, 30 parts of sea cucumber polysaccharides, 25 parts of ginseng extract, 25 parts of Acanthopanax acanthopanax extract, 15 parts of white kidney bean extract, and 20 parts of Poria cocos extract, place them in a blender and mix for 15 minutes, and then use an automatic packaging machine to package them to obtain a powder product.

[0045] The weight average molecular weight of sea cucumber polysaccharide is 18.7kD, the polysaccharide content is 64.2%, the sulfate group content is 28.4%, and free sulfate groups are not detected.

[0046] The peptide content of sea cucumber oligopeptides is 86.1%, of which peptides with a molecular weight of less than 1000Da account for 96.1%.

[0047] The ginseng extract, Acanthopanax breviscapus extract, Kidney Bean extract, and Poria cocos extract are the same as those in Example 1.

[0048] Comparative Example 1: A composition for improving hyperglycemia in pets, comprising: 40 parts of sea cucumber powder, 20 parts of ginseng powder, 20 parts of Acanthopanax short-stalked powder, 10 parts of white kidney bean powder, and 10 parts of Poria powder.

[0049] The preparation method comprises:

[0050] (1) Accurately weigh 40 parts of sea cucumber powder, 20 parts of ginseng powder, 20 parts of Acanthopanax short-stalked powder, 10 parts of white kidney bean powder, and 10 parts of Poria cocos powder, grind them into powder, mix them in a blender for 15 minutes, and then package them in an automatic packaging machine to obtain a powder product.

[0051] Comparative Example 2: A composition for improving hyperglycemia in pets, comprising: 20 parts of sea cucumber oligopeptides, 20 parts of sea cucumber polysaccharides, 10 parts of white kidney bean extract, and 10 parts of Poria cocos extract.

[0052] This comparative example is the same as Example 1 except for the following differences.

[0053] The difference is that the Acanthopanax brevis extract and the Ginseng extract are removed.

[0054] Comparative Example 3: A composition for improving hyperglycemia in pets, comprising: 30 parts of sea cucumber polysaccharide, 25 parts of ginseng extract, 25 parts of Acanthopanax breviscapus extract, and 15 parts of white kidney bean extract.

[0055] This comparative example is the same as Example 2 except for the following differences.

[0056] The difference is: removing sea cucumber oligopeptides and Poria cocos extract.

[0057] Experimental verification 1: The products obtained in Examples 1 and 2 of the present invention and Comparative Examples 1, 2 and 3 were used as samples, and their effects were verified by animal experiments on hyperglycemic mice.

[0058] 80 healthy Kunming mice weighing 20-24g were selected and fed adaptively for 3 days. Ten mice were randomly selected as the normal control group, and the remaining 70 mice were used to build hyperglycemia model mice. After fasting for 12 hours, the mice were intraperitoneally injected with alloxan at a dose of 120mg / (kg·bw). After 5 days of free diet, they were fasted again for 12 hours without water confinement. Then, blood was collected from the tail vein of the mice to measure the blood sugar level. Blood sugar level > 10mmol / L indicated that the hyperglycemia mouse model was successfully established. Among the 70 mice involved in the modeling, 62 mice were successfully modeled, and 60 mice were randomly selected and divided into 6 groups (model control group, experimental groups 1, 2, 3, 4, and 5), with 10 mice in each group.

[0059] Table 1. Experimental scheme of oral gavage in each group of mice

[0060] Group Mouse type Gavage samples dose Normal control group Normal mice Normal saline 0.4ml Model control group Hyperglycemia model mice Normal saline 0.4ml Experimental Group 1 Hyperglycemia model mice Example 1 Product 1g / kg Experimental Group 2 Hyperglycemia model mice Example 2 Product 1g / kg Experimental Group 3 Hyperglycemia model mice Comparative Example 1 Product 1g / kg Experimental Group 4 Hyperglycemia model mice Comparative Example 2 Product 1g / kg Experimental Group 5 Hyperglycemia model mice Comparative Example 3 Product 1g / kg

[0061] According to the requirements of Table 1, each group of mice was given an intragastric gavage test once a day for 28 consecutive days.

[0062] After a period of feeding, normal mice will show a steady increase in weight, no insulin resistance, and a relatively constant ratio of organs to body weight. However, the weight gain of hyperglycemic mice will be inhibited, and persistent high blood sugar will lead to a decrease in the body's sensitivity to insulin, insulin resistance, organ damage, etc.

[0063] Body weight determination: The mice in each group were fasted but not watered for 12 h after oral gavage on days 0, 14, and 28, and their body weights were then determined.

[0064] Fasting blood glucose determination: Mice in each group were fasted but not watered for 12 h on day 0 and day 28 after gavage, and blood glucose levels were determined by sampling blood from the tail vein of each mouse.

[0065] Fasting serum insulin determination: After oral gavage for 28 days, mice in each group were fasted but not watered for 12 hours, and blood was collected from each mouse to determine its serum insulin level.

[0066] Insulin resistance level: The average insulin resistance index (HOMA-IR) of each group of mice = fasting blood glucose (mmol / L) × fasting serum insulin (μU / mL) / 22.5.

[0067] Organ index: After 28 days of gavage, mice in each group were killed by cervical dislocation and their thymus and spleen were weighed to calculate the organ index. Thymus index = average thymus weight (mg) / average mouse weight (g); spleen index = average spleen weight (mg) / average mouse weight (g).

[0068] Table 2. Body weight measurement results of mice in each group ( n=10)

[0069]

[0070] The weight of mice in each group is shown in Table 2. The results showed that after 28 consecutive days of gavage, the weight of mice in the normal control group increased steadily, while the weight of mice in the hyperglycemia model control group increased very slowly and was inhibited.

[0071] Compared with the model control group, the weight suppression phenomenon of mice in Experimental Groups 1, 2, 3, 4, and 5 was controlled, and weight growth occurred. The effects of Examples 1 and 2 were better than those of Comparative Examples 1, 2, and 3, and the weight growth reached the level of mice in the normal control group after 28 days. This shows that the present invention can improve the emaciated state of hyperglycemic mice, play a role in increasing weight, and the components of the formula have a coordinated synergistic effect.

[0072] Table 3. Fasting blood glucose, serum insulin and insulin resistance levels of mice in each group ( n=10)

[0073]

[0074] The blood glucose, serum insulin and insulin resistance of each group of mice are shown in Table 3. Compared with the normal control group mice, the hyperglycemia model mice were successfully modeled and initially showed a hyperglycemic state. After 28 days of gavage experiments, compared with the model control group, the fasting blood glucose content, fasting serum insulin content and insulin resistance level of the mice in Experimental Groups 1, 2, 3, 4 and 5 decreased, among which the effects of Examples 1 and 2 were much better than those of Comparative Examples 1, 2 and 3, and the mice in Experimental Groups 1 and 2 could be restored to the level of mice in the normal control group. This shows that the present invention has a good hypoglycemic effect, can reduce the "toxicity" of sustained high blood sugar, and can also improve insulin sensitivity and improve insulin resistance. The synergistic effect between the components can protect the pancreatic β cells from being over-stimulated and prevent excessive secretion of insulin.

[0075] Table 4. Organ index of mice in each group ( n=10)

[0076] Group Thymus index / (mg / g) Spleen index / (mg / g) Normal control group 1.63±0.34 4.32±0.23 Model control group 0.78±0.51 2.97±0.71 Experimental Group 1 1.57±0.18 4.22±0.81 Experimental Group 2 1.54±0.37 4.41±0.64 Experimental Group 3 0.93±0.43 3.34±0.76 Experimental Group 4 1.21±0.25 3.77±0.50 Experimental Group 5 0.96±0.28 3.41±0.69

[0077] The organ indexes of mice in each group are shown in Table 4. Compared with the normal control group mice, the thymus and spleen indexes of the hyperglycemia model mice were significantly decreased and damaged. After 28 days of gavage experiment, compared with the model control group, the thymus and spleen indexes of the mice in Experiment 1, 2, 3, 4, and 5 groups were improved, and the effect of Experiment 1 and 2 groups was better than that of Experiment 3, 4, and 5 groups. It shows that the present invention can improve organ damage, protect and repair the pancreas, and restore its normal function through the synergistic effect of various components.

[0078] Experimental verification 2: The products obtained in Examples 1 and 2 of the present invention were used as samples, and their effects were verified through pet experiments.

[0079] Five blue cats and five Burmese cats with high blood sugar (not developed into diabetes) were selected. At the beginning of the test, the fasting blood sugar data of each pet was measured and recorded, and then the pets were fed according to the scheme in Table 5. After 4 weeks, the fasting blood sugar of each pet was tested again. At the same time, the diet, fur and other external manifestations of the pets were observed and recorded during the feeding period.

[0080] Table 5. Feeding plan for each group of pets

[0081] Group Feeding regimen Example composition addition amount Feeding amount Feeding time Blue Cat Group Ordinary cat food + product of Example 1 20g / kg cat food No dietary restrictions 4 weeks Burmese cat group Ordinary cat food + Example 2 product 20g / kg cat food No dietary restrictions 4 weeks

[0082] The changes in fasting blood sugar of each group of pet cats before and after 4 weeks of feeding are shown in Figure 1 , Figure 2. When fed with ordinary cat food and without dietary restrictions, the blood sugar of the high-glycemic pet cats participating in the experiment was still improved and significantly reduced, and basically reached normal levels after 4 weeks. At the same time, it was observed that the early symptoms of the pet cats, such as polydipsia, polyphagia, and polyuria, gradually alleviated and returned to normal, and the fur became smooth from fluffy and dull. This shows that the present invention can improve the symptoms of high blood sugar in pets before high blood sugar develops into diabetes, reduce insulin resistance, restore the normal function of pancreatic β cells, and block the development of persistent high blood sugar into diabetes.

[0083] Although the present invention is described through specific embodiments, the protection scope of the present invention is not limited thereto, and any person familiar with the technical field can make equivalent substitutions or changes according to the technical solution and inventive concept of the present invention within the technical scope disclosed by the present invention, and these changes should be covered by the protection scope of the present invention.

Claims

1. A composition for improving hyperglycemia in pets, comprising:

2. The composition for improving hyperglycemia in pets according to claim 1, characterized in that: The sea cucumber oligopeptides and sea cucumber polysaccharides are prepared in the following manner: S1. Crush the dried sea cucumber, add water to boil, homogenize, and stir to obtain a liquid feed; S2. The feed solution is ultrasonically treated, and a composite protease of 0.2 to 0.5% of the feed solution volume is added for enzymatic hydrolysis, the enzymatic hydrolysis temperature is 50 to 55 ° C, the enzymatic hydrolysis pH is 7.0 to 8.0, and the enzymatic hydrolysis time is 2 to 3 h, wherein the composite protease papain: medium temperature α-amylase = 1: (1 to 3), to obtain a first enzymatic solution; S3. Add 0.2 to 0.5% of the volume of the composite protease for enzymatic hydrolysis, the enzymatic hydrolysis temperature is 55 to 60 ° C, the enzymatic hydrolysis pH is 8.0 to 9.0, the enzymatic hydrolysis time is 3 to 5h, the composite protease trypsin: alkaline protease: neutral protease = (3 to 5): (2 to 4): (1 to 2), to obtain a second enzymatic solution; S4. The second enzymatic hydrolysate is centrifuged to obtain a supernatant, and the supernatant is passed through a membrane device with a molecular weight cutoff of 3000Da to obtain a permeate and a retentate. The permeate is concentrated and spray-dried to obtain sea cucumber oligopeptides, and the retentate is concentrated and freeze-dried to obtain sea cucumber polysaccharides.

3. The composition for improving hyperglycemia in pets according to claim 2, characterized in that: Preferably, the raw material of the ginseng extract is Changbai Mountain ginseng; Preferably, the raw material of the sea cucumber oligopeptide and / or sea cucumber polysaccharide is sea cucumber; More preferably, the raw material of the sea cucumber oligopeptide and / or sea cucumber polysaccharide is sea cucumber Stichopus japonicus and / or sea cucumber Stichopus japonicus; Preferably, in step S1, 5-7 times the mass of water is added and boiled for 30 minutes, homogenized by a colloid mill, and then 5-10 times the mass of water is added and stirred evenly; Preferably, in step S2, the ultrasonic power is 300-400 W, and the ultrasonic time is 40-60 min.

4. The composition for improving pet hyperglycemia according to claim 2, characterized in that: The sea cucumber polysaccharide is a low molecular weight sea cucumber polysaccharide with a weight average molecular weight of <25 kD, a polysaccharide content of >50%, a sulfate group content of ≥20%, and no free sulfate group detected.

5. The composition for improving hyperglycemia in pets according to claim 2, characterized in that: The peptide content of the sea cucumber oligopeptide is greater than 80%, wherein the molecular weight of more than 95% of the peptides is less than 1000Da.

6. The composition for improving hyperglycemia in pets according to claim 2, characterized in that: The ginseng extract contains ginsenosides ≥3%, peptides ≥15%, and more than 80% of the peptides have molecular weights less than 1000Da.

7. The composition for improving hyperglycemia in pets according to claim 2, characterized in that: The Acanthopanax breviscapus extract is obtained by enzymatic extraction, wherein the total saponin is ≥2.0% and the total flavonoids is ≥0.3%.

8. The composition for improving hyperglycemia in pets according to claim 2, characterized in that: The white kidney bean extract is obtained by enzymatic extraction, wherein the α-amylase inhibitor activity is ≥2000u / g, and the plant lectin activity is ≤0.4mg / mL.

9. The composition for improving hyperglycemia in pets according to claim 2, characterized in that: The Poria cocos extract is obtained by enzymatic extraction, wherein the Poria cocos polysaccharide content is ≥20%.

10. The composition for improving hyperglycemia in pets according to claim 2, characterized in that The composition for improving pet hyperglycemia is prepared in the form of any one of powder, granules, tablets, capsules, pills and oral liquid.

Images